Trending Topics

Ebola Vaccine Sees Early Success in Human Trials

Apr 13, 2015 06:03 PM EDT
A 26-year-old male participant receives an experimental Ebola vaccine in early phase clinical trials.
(Photo : NIAID)

The Ebola outbreak, which made headlines just last year, is slowly but surely coming under control, according to the World Health Organization and public health initiatives. Now, researchers are saying that there is hope that it will soon never resurface in epidemic proportions again, as an experimental vaccine called VSV-ZEBOV was recently found to be both safe and effective in early human trials.

Ebola isn't exactly a virus that needs an introduction (Explore the history of Ebola here). It has been causing complete disarray in West Africa for the greater part of the last 15 months, jumping from Guinea's most remote regions to its capital, and on to Liberia, Sierra Leone, and other bordering countries. Symptoms include severe fever, vomiting, diarrhea, and horrific bleeding from the eyes, ears, mouth, and rectum.

One of the reasons that Ebola has been so difficult to treat and contain is that we know very little about it. Ebola lives a particularly short life in the human body, either being defeated by modern medicine or killing its victims in short order.

This means that researchers have very little time to observe the virus in action, as doctors simultaneously struggle to save their patient. Experts recently discovered what could be the "Achilles heel" of Ebola and other members of the nonsegmented negative-strand (NNS) RNA virus family. However, potential treatments taking advantage of this discovery are still many years in the making.

That's why immunotherapy - using exposure via vaccine - would be most preferable. Experts may not know how to stop Ebola in its tracks, but the human immune system is a faster learner.

Early phase clinical trials with VSV-ZEBOV recently showed that this could indeed be the best approach, with most volunteers who received the vaccine developing antibodies against Ebola within 14 days of injection. In four weeks time, all 40 injected participants (aside from 12 placebo controls) developed an efficient immune system response.

Most importantly, the injection did not prompt any Ebola symptoms in any of the inoculated. And that's good because such an adverse reprocess should not be impossible. (Scroll to read on...)

(Photo : CDC Global)

On The Safety of This Vaccine

VSV-ZEBOV was developed by scientists at the Public Health Agency of Canada (PHAC) and does not use the actual Zair species that has been ravaging West Africa. Instead, its base is an attenuated vesicular stomatitis virus - something that would normally affect cattle. This virus was genetically modified in a controlled setting to contain a gene segment key in the Zaire species. In this way, the vaccine cannot cause an Ebola infection, but can still teach the human immune system to target the mechanisms behind those essential genes.

"The prompt, dose-dependent production of high levels of antibodies following a single injection and the overall favorable safety profile of this vaccine make VSV-ZEBOV a promising candidate that might be particularly useful in outbreak interventions," Richard T. Davey Jr. of the US National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) concluded in a recent statement.

The results of the trials, which were conducted independent of the PHAC through the NIAID and the Walter Reed Army Institute of Research (WRAIR), were published in the New England Journal of Medicine.

Still, it's important to note that this isn't the only promising Ebola vaccine. Another vaccine, one that is inhalable as opposed to traditional injections, showed promise in primate trials back in November. That's a boon not only for humans, but gorillas as well, as great apes in Ebola affected regions continue to face alarming mortality rates and population decline.

For more great nature science stories and general news, please visit our sister site, Headlines and Global News (HNGN).

- follow Brian on Twitter @BS_ButNoBS.

© 2018 All rights reserved. Do not reproduce without permission.

Join the Conversation

Email Newsletter
About Us Contact Us Privacy Policy Terms&Conditions
Real Time Analytics